AU Patent

AU2013204879B2 — Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

Assigned to Vifor International AG · Expires 2015-10-29 · 11y expired

What this patent protects

Document 1 -4/12/2013 The present invention is directed to crosslinked cation exchange polymers comprising a fluoro group and an acid group, pharmaceutical compositions of these polymers, compositions of a linear polyol and a salt of such polymer. Crosslinked cation exchange 5 po…

USPTO Abstract

Document 1 -4/12/2013 The present invention is directed to crosslinked cation exchange polymers comprising a fluoro group and an acid group, pharmaceutical compositions of these polymers, compositions of a linear polyol and a salt of such polymer. Crosslinked cation exchange 5 polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio are also described. These polymers and compositions are useful to bind potassium in the gastrointestinal tract.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013204879B2
Jurisdiction
AU
Classification
Expires
2015-10-29
Drug substance claim
No
Drug product claim
No
Assignee
Vifor International AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.